Atrial Fibrillation - ClinicalTrials.gov

Mobile Health Intervention for Rural Atrial Fibrillation

This is a controlled clinical trial carried out to determine the effect of a smartphone-based intervention called an embodied conversational agent on health outcomes in people with atrial fibrillation. The study will enroll 264 patients who live in rural, Western Pennsylvania, who have atrial fibrillation. Intervention participants will be sent a smartphone with a relationship agent that simulates conversation and gives advice, support, and assistance with chronic disease self-management. Participants in Control will get a smartphone with WebMD health software.

Source link: https://clinicaltrials.gov/ct2/show/NCT04076020

Implantable Cardiac Monitor to Detect Atrial Fibrillation in Patients With MINOCA

About 5-6% of patients with acute myocardial infarction have myocardial infarction with non-obstructive coronary arteries on coronary angiography, and up to 50% of these patients are still lacking appropriate diagnosis and treatment. For the first time, the aim of this study is to determine the occurrence of first-diagnosed atrial fibrillation with the use of ICM in patients with MINOCA.

Source link: https://clinicaltrials.gov/ct2/show/NCT05326828

Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis (SAFE-D)

In addition, the effect of anticoagulation in dialysis patients may vary from those studied in clinical studies, and in particular those receiving dialysis.

Source link: https://clinicaltrials.gov/ct2/show/NCT03987711

Comparison of Remimazolam With Flumazenil vs. Propofol TIVA During RFCA for Atrial Fibrillation

Adult patients with ventricular fibrillation who are undergoing radiofrequency catheter ablation under general anesthesia are randomized to receive either remimazolam with flumazenil or propofol total intravenous anesthesia as the key anesthetics. The primary result of the study is a comparison of the time to the first eye opening responding to a doctor's request that each drug be discontinued between the two groups.

Source link: https://clinicaltrials.gov/ct2/show/NCT05397886

Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation

Patients with significant renal insufficiency, 15mg quaque die Patients with moderate to severe renal insufficiency, weight u226460 kg, or a mixture of P-gp inhibitors, 30 million patients die. After 12 weeks of clinical observation, the population pharmacokinetics of Edoxaban in Chinese patients with non-valvular atrial fibrillation will be determined. The ENGAGE PopPK model suitable in Chinese Patients with Non-Valvular Atrial Fibrillation will be developed.

Source link: https://clinicaltrials.gov/ct2/show/NCT05320627

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions